ZD 1542
Alternative Names: ICI D 1542Latest Information Update: 07 Apr 1999
At a glance
- Originator AstraZeneca
- Class Antiplatelets; Peripheral vasodilators
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed